These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27925864)

  • 1. Intravenous use of intranasal naloxone: A case of overdose reversal.
    Das S; Shah N; Ghadiali M
    Subst Abus; 2017; 38(1):18-21. PubMed ID: 27925864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of overdose on fentanyl being illicitly sold as heroin with naloxone nasal spray: A case report.
    Fareed A; Buchanan-Cummings AM; Crampton K; Grant A; Drexler K
    Am J Addict; 2015 Aug; 24(5):388-90. PubMed ID: 26039379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone (Narcan) nasal spray for opioid overdose.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):1-2. PubMed ID: 26714239
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
    Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
    Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.
    Mundin G; McDonald R; Smith K; Harris S; Strang J
    Addiction; 2017 Sep; 112(9):1647-1652. PubMed ID: 28430384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naloxone without the needle - systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal.
    Strang J; McDonald R; Alqurshi A; Royall P; Taylor D; Forbes B
    Drug Alcohol Depend; 2016 Jun; 163():16-23. PubMed ID: 26996745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
    Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
    Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two cases of intranasal naloxone self-administration in opioid overdose.
    Green TC; Ray M; Bowman SE; McKenzie M; Rich JD
    Subst Abus; 2014; 35(2):129-32. PubMed ID: 24821348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose.
    Yokell MA; Zaller ND; Green TC; McKenzie M; Rich JD
    J Opioid Manag; 2012; 8(1):63-6. PubMed ID: 22479887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
    McDonald R; Lorch U; Woodward J; Bosse B; Dooner H; Mundin G; Smith K; Strang J
    Addiction; 2018 Mar; 113(3):484-493. PubMed ID: 29143400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prehospital Naloxone Administration as a Public Health Surveillance Tool: A Retrospective Validation Study.
    Lindstrom HA; Clemency BM; Snyder R; Consiglio JD; May PR; Moscati RM
    Prehosp Disaster Med; 2015 Aug; 30(4):385-9. PubMed ID: 26061280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.
    Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J
    J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with naloxone administration in an opioid dependent sample.
    Kenney SR; Anderson BJ; Bailey GL; Stein MD
    J Subst Abuse Treat; 2018 Jan; 84():17-20. PubMed ID: 29195589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose.
    Strickland JC; Marks KR; Smith KE; Ellis JD; Hobelmann JG; Huhn AS
    Int J Drug Policy; 2022 Aug; 106():103751. PubMed ID: 35636070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An increase in per-patient naloxone requirements in an opioid epidemic.
    Birmingham LE; Nielson JA
    Am J Emerg Med; 2017 Dec; 35(12):1958-1959. PubMed ID: 28633907
    [No Abstract]   [Full Text] [Related]  

  • 16. Intranasal naloxone administration for treatment of opioid overdose.
    Robinson A; Wermeling DP
    Am J Health Syst Pharm; 2014 Dec; 71(24):2129-35. PubMed ID: 25465584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.
    McDonald R; Danielsson Glende Ø; Dale O; Strang J
    Drug Alcohol Rev; 2018 Feb; 37(2):205-215. PubMed ID: 28597483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities.
    Beletsky L; Ruthazer R; Macalino GE; Rich JD; Tan L; Burris S
    J Urban Health; 2007 Jan; 84(1):126-36. PubMed ID: 17146712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Working together: Expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond.
    Lenton S; Dietze P; Olsen A; Wiggins N; McDonald D; Fowlie C
    Drug Alcohol Rev; 2015 Jul; 34(4):404-11. PubMed ID: 25272281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths.
    Maxwell S; Bigg D; Stanczykiewicz K; Carlberg-Racich S
    J Addict Dis; 2006; 25(3):89-96. PubMed ID: 16956873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.